Skip to main content
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 2010 Mar 10;19(5):987–999. doi: 10.1002/pro.376

Structure of the catalytic domain of the human mitochondrial Lon protease: Proposed relation of oligomer formation and activity

Javier García-Nafría 1, Gabriela Ondrovičová 2, Elena Blagova 1, Vladimir M Levdikov 1, Jacob A Bauer 2, Carolyn K Suzuki 3, Eva Kutejová 2,4,*, Anthony J Wilkinson 1, Keith S Wilson 1,*
PMCID: PMC2868241  PMID: 20222013

Abstract

ATP-dependent proteases are crucial for cellular homeostasis. By degrading short-lived regulatory proteins, they play an important role in the control of many cellular pathways and, through the degradation of abnormally misfolded proteins, protect the cell from a buildup of aggregates. Disruption or disregulation of mammalian mitochondrial Lon protease leads to severe changes in the cell, linked with carcinogenesis, apoptosis, and necrosis. Here we present the structure of the proteolytic domain of human mitochondrial Lon at 2 Å resolution. The fold resembles those of the three previously determined Lon proteolytic domains from Escherichia coli, Methanococcus jannaschii, and Archaeoglobus fulgidus. There are six protomers in the asymmetric unit, four arranged as two dimers. The intersubunit interactions within the two dimers are similar to those between adjacent subunits of the hexameric ring of E. coli Lon, suggesting that the human Lon proteolytic domain also forms hexamers. The active site contains a 310 helix attached to the N-terminal end of α-helix 2, which leads to the insertion of Asp852 into the active site, as seen in M. jannaschii. Structural considerations make it likely that this conformation is proteolytically inactive. When comparing the intersubunit interactions of human with those of E. coli Lon taken with biochemical data leads us to propose a mechanism relating the formation of Lon oligomers with a conformational shift in the active site region coupled to a movement of a loop in the oligomer interface, converting the proteolytically inactive form seen here to the active one in the E. coli hexamer.

Keywords: ATP-dependent protease, Lon protease, catalytic dyad, mitochondria, oligomerization and activity

Introduction

ATP-dependent proteases are important for cellular homeostasis, present in all organisms, and degrade abnormal and denatured proteins as well as short-lived regulatory ones.1 There are a number of ATP-dependent protease families, of which one is the Lon proteases. Indeed the Escherichia coli enzyme (EcLon) was the first ATP-dependent protease to be discovered2 and probably remains the most studied to date. Members of the Lon family are ubiquitous in bacteria, archaea, and eukaryotes, where they are found in chloroplasts,3 mitochondria,4 and peroxisomes.5 In mitochondria, metabolic activity generates high levels of free radicals which then oxidize proteins leading to their aggregation; this is believed to be a significant cause of aging6 and neurodegenerative disease.7 Many mitochondrial proteins are synthesized in the cytosol and transported to the mitochondria, where they are assembled into large complexes. Misassembled, nonassembled, and oxidatively damaged proteins must be recognized and degraded, otherwise they can be toxic to the cell. The human mitochondrial Lon protease (hLon) has been shown to degrade oxidized proteins including aconitase.8hLon has also been shown to bind to mitochondrial DNA in a region overlapping the mitochondrial DNA (mtDNA) promoter and to GC rich sequences along the mtDNA.9,10,11hLon is believed to be involved in mtDNA replication, translation, or repair because it has been shown to immunoprecipitate with both mitochondrial twinkle helicase and the mtDNA polymerase γ catalytic subunit A (polγA).12 The mitochondrial Lon proteases are associated with mitochondrial nucleoid proteins such as mtSSB and the recently identified PDIP38.13 Lon has been shown to be present in mitochondrial nucleoids.14 A detailed knowledge of the Lon 3D structure is required for a full understanding of these processes.

There are two Lon families: LonA and LonB. The polypeptide chain of the LonA family members consists of an N-terminal domain, a central ATPase (AAA+) domain and a proteolytic domain (henceforth termed LonP) at the C-terminus. In contrast, the LonB family lacks the N-terminal domain and shows differences in the residues conserved in the AAA+ domain and the proteolytic domain.15hLon belongs to the LonA family. The N-terminal domain is thought to be involved in the selective binding of substrates as well as in the oligomeric assembly of the protease, as shown for the Brevibacillus thermoruber enzyme.16 The X-ray structure of the N-terminal domain of EcLon has been reported17 and shown to be similar to that of BPP1347 (PDB code: 1zbo), a member of the cluster of orthologous group (COG) 2802 of proteins of unknown function.

The ATPase domain belongs to the well-characterized AAA+ superfamily of proteins.18 It is composed of two subdomains, a β/α-domain upstream of an α-domain. Many structures of AAA+ superfamily proteins have been reported, including those of the α-domains, of the Lon proteases from E. coli19 and B. subtilis (PDB code 1x37). In Lon, the role of this domain appears to be the unfolding of substrate proteins before their cleavage by the proteolytic domain.20 The ATPase domain has also been proposed to be involved in DNA binding from studies of the B. thermoruber enzyme.16

The C-terminal proteolytic domain contains a Ser-Lys dyad at the active site. Studies in yeast have shown that the ATPase domain and proteolytic domain, even when expressed separately, are able to interact within the mitochondrion and can fully replace intact Lon.21 There appear to be an allosteric interaction between the two domains, and the proteolytic domain is inactive in protein degradation when the AAA+ cassette is not present. However, the proteolytic domain of EcLon appears to hydrolyze small peptides22 without AAA+ cassette participation. Crystal structures of the Lon proteolytic domain from a eubacterium and two archaea have been determined and all have similar overall folds.

The structure from the eubacterium E. coli (EcLon: PDB code 1rre) was the first to be determined, it had a unique fold and crystallized as a noncrystallographic hexamer.23 The catalytic serine had been mutated to alanine (S679A). The active site was open to the surface suggesting it was accessible to substrates. This was followed by the structures from two archaea Methanocaldococcus jannaschii24 and Archaeoglobus fulgidus,25 henceforth MjLonP and AfLonP with PDB codes 1xhk and 1z0b, respectively. The MjLonP active site again revealed a Ser-Lys dyad. The structure appeared to form a dimer in the asymmetric unit but this was reported not to be of biological significance. An unexpected feature was that the N-terminal region of the helix carrying the catalytic serine was a 310 helix and not a β-strand as in EcLonP, bringing a new residue into the active site, Asp547, which made a salt bridge with the catalytic lysine.

For AfLonP, the structures of several mutants were determined, some but not all of which contained a noncrystallographic hexamer similar to that in EcLonP, and some of which were monomers. In all the AflonP structures, the catalytic serine pointed away from the lysine and the N-terminal region of the helix carrying the serine was a β-strand. Mutation of the glutamate, equivalent to the aspartate in the MjLonP active site, showed no change in ATP-independent activity, but did show a decrease in ATP-dependent protease activity, and was taken to indicate that this aspartate was not directly involved in catalysis.

Structures of a number of other Ser-Lys dyad proteases have been determined.26,27 In particular, the structures of two VP4 proteases from the Birnaviruses (PDB codes: 2pnl and 2gef)28,29 share the same overall topology as the LonP domains, and indeed they were initially identified as noncanonical Lon proteases.30 These are monomeric single domain proteins expressed as part of a longer viral polypeptide containing several preproteins. The role of the VP4 protease is to produce the mature forms of the individual proteins. One structure (2gef) contains a well-defined Ser-Lys dyad. In the second (2pnl), the lysine was mutated to alanine allowing the formation of a covalent intermediate providing direct evidence for the mechanism involving nucleophilic attack by the serine. The active sites of 2gef and 2pnl superimpose closely, and the mutation of lysine to alanine has less impact on the conformation.

Here we present the crystal structure of the proteolytic domain of human mitochondrial Lon protease (hLonP) at 2 Å resolutions, the first structural data for an eukaryotic Lon. The active site is blocked by an aspartate as seen in MjLon despite the sequence in this region being almost identical to that of EcLon. On the basis of the hLonP structure, together with those of homologous LonPs and our biochemical data regarding oligomerization state and activity, we propose a mechanism by which hexamer formation is coupled to a conformational transition at the active site which converts the inactive conformation seen here to one resembling that seen in EcLon.

Results

The hLonP protomer

The crystal structure of hLonP was solved by molecular replacement using EcLon (PDB: 1rre) as a search model and was refined at 2.0 Å spacing. It is curious to note that, similar to the EcLon and AfLon structures, problems were encountered with twinning and the assignment of the space group.

The proteolytic domain used for crystallogenesis contained residues 741–959, but due to presumed degradation of the protein in the crystallization drop, the protein in the crystal corresponds to residues 754–959, confirmed by N-terminal sequencing. There are six protomers in the asymmetric unit with essentially identical folds as shown by the average pairwise rms difference in Cα positions between chains of 0.44 Å. The protomer structure has nine β-strands and seven α-helices [Fig. 1(A)]. The biggest differences between the protomers lie in the loops connecting the secondary structural elements with the largest deviations for residues 785–797. Up to six residues at the N-termini (754–759) and 11 at the C-termini (949–959) of all six chains are missing in the electron density maps and are assumed to be disordered. In addition, a number of residues in surface loops are missing in each protomer, with a maximum of 13 residues in chain B.

Figure 1.

Figure 1

The hLonP protomer. A: Stereo ribbon diagram color ramped from N- to C-terminus. B: In the same orientation as (A), the structures of E. coli (coral), M. janaschii (blue), and A. fulgidus (yellow) LonP represented as worms superimposed on that of hLonP (green), confirming their high similarity. The main differences are in the loops and at the N-terminus of α2. Ser855 and Lys898 composing the catalytic dyad are shown as spheres for the human enzyme. This Figure and Figures 3 and 4 were created with CCP4mg.31

The overall fold is similar to that of other known LonP domains [Fig. 1(B)], and therefore, only differences between the present structure and EcLonP will be described. The sequences of the four LonP domains for which the structure is known are aligned in Figure 2. To aid comparison, the numbering scheme for the secondary structural elements of EcLonP will be used throughout. As in EcLonP, strands β1–β4 form a mixed parallel/antiparallel β−sheet. β1 and β2 are connected by a type I β−turn, but there was no density for the loop connecting β2–β3 (785–797) and it is presumed to be disordered. Following β3 is helix α1 and then the short α1a (a hydrogen-bond turn in EcLon). After this short helix comes β4 but β5 is replaced in hLonP by an extension to α2. This extension begins as a hydrogen-bonded turn in a close to helical conformation (residues 850–852), becomes a 310 helix (residues 853–856), and from Gly857 α2 continues as a normal α−helix. This extension causes a substantial conformational change in the region of the active site and is of considerable significance for our proposal regarding LonP activity. Following α2, there is a short β-bridge in EcLon, which is absent from hLon. The second subdomain comprises a parallel β-sheet (β6, β9, and β10) flanked by α3, α4, α5, and α6. This subdomain shows no significant changes from EcLonP with one exception: α4 was a 310 helix in EcLonP but is a normal α-helix here.

Figure 2.

Figure 2

Sequence alignment of the Lon proteolytic domains for which the structure is known. The secondary structure at the top corresponds to the human orthologue, whereas that at the bottom corresponds to EcLonP. Invariant positions are shaded and conserved positions are boxed. Figure created using CLUSTAL W32 and ESPript.33

hLonP dimers

Analysis of the surface contacts with PISA34 suggests that four hLonP protomers form two equivalent dimers, whereas the other two are monomers. Unfortunately, the ΔiG values calculated by PISA fall within the uncertainty limit of the method making it difficult to distinguish reliably using buried surface area alone whether A:B and C:D form dimers with E and F forming monomers, or if A:E and C:F are the dimers with B and D as monomers. However, this can be clarified by comparison with other Lon sequences and 3D structures.

In the hypothetical A:E and C:F dimers, the two protomers are related by approximate twofold rotational symmetry, with interactions primarily between their α1 helixes from which residues interact with their counterparts in the second subunit. A multiple sequence alignment of 60 LonA sequences from SWISSPROT shows that although this particular region is generally well conserved, a number of key residues are not, notably Arg815 and Lys888. Furthermore, it is difficult to imagine how this type of dimer would give rise to the type of hexamer seen in electron micrographs of full-length Lon, nor does it relate to the interface of the hexamers seen in the EcLonP and AfLonP crystals. This interaction can be presumed to be an artefact of crystal packing and is unlikely to be of physiological significance.

In marked contrast, the A:B/C:D dimer interface is similar to that formed between adjacent subunits of the EcLonP and AfLonP hexamers. α1 packs against β3 in the adjacent subunit [Fig. 3(A)] and the loop between β7 and β8 makes intersubunit contacts with β2. The interactions are mainly hydrophilic and 1520 Å2 of accessible surface area are buried, similar to the value in EcLonP. However, unlike EcLonP, the loop following β4 does not contribute any intermolecular contacts, a result of interference from the N-terminus. Met756 in the N-terminus itself packs between Phe779 of the same subunit and the aliphatic portion of Lys888 of the adjacent one. Additionally, Tyr757 forms a hydrogen bond with Thr886 of the adjacent subunit, further stabilizing the position of the N-terminal loop. We conclude that the biologically significant dimers are the protomer pairs A:B and C:D.

Figure 3.

Figure 3

The subunit–subunit interface in LonP and relation between oligomerization and activation. A: Stereo view of the hLonP dimer interface, formed by chains (A) (gray) and (B) (blue) shown as ribbons. α1 of one chain packs against β-sheet 1 of the adjacent subunit. Side chains (cylinders with carbons in green) are shown for those residues involved in direct intersubunit contacts together with the H-bonds between them. The loop emerging from β4 (black) does not make any contacts with the adjacent subunit. Residues in the active site are depicted as cyan cylinders. B: Stereo view of adjacent subunits from the E. coli LonP hexamer colored coral and yellow. The side chains are shown as cylinders (green) for those residues involved in direct intersubunit contacts. The extended loop (residues 669–674)—caused by the unfolding of the beginning of α2 in hLon—is in red, and makes additional contacts with the adjacent subunit. Residues in the active site are depicted as cyan cylinders. C: Structural differences between the monomeric/dimeric inactive state (represented by hLon) and the proposed hexameric active state (represented by EcLon). The surfaces of two adjacent subunits of the EcLonP hexamer are shown in blue and white: the extensive surface buried in this interface is evident. For EcLonP, the following features are shown. (i) The extended loop residues 667–681 (including a length of β-strand) at the N-terminal end of α2 (red ribbon). This makes a substantial contribution to the interface. (ii) The side chains (red cylinders) of two key residues Asp676 and Trp603 (equivalent to Asp852 and Trp770 in hLonP). For hLonP are shown: (i) the catalytic residues Ser855, Lys898, and Thr880 (cylinders colored by atom type), (ii) the N-terminal segment of hLonP α2 as a black ribbon, (iii) the side chains of the two residues as black cylinders (Asp852 and Trp770) which block the active site, and (iv) the chain in the neighborhood of the catalytic serine as a pale green ribbon. The hLonP N-terminal segment of α2 with the helical fold places Asp852 directly in the active site with Trp770 physically blocking access, making the monomeric/dimeric form inactive. Thus, in EcLonP, the N-terminal section of α2 (which is helical in hLon) is unwound so as to contact the adjacent subunit. This movement carries Asp676 (equivalent to Asp852 in human) away from the active site. The loop is H-bonded to the main chain of Trp603 whose side chain is also pulled away from the active site.

The active site

LonA proteins are serine proteases, with a Ser-Lys dyad in which a lysine assists the catalytic serine in proteolytic cleavage.15 A third catalytic residue, a serine or a threonine, is present in some but not all such proteases.26,27,35 The hLonP active site has an underlying similarity to that of EcLonP, with the positions of several key residues in and around the active site (Pro854, Ser855, Ala856, Gly857, Thr880, and Lys898) being closely conserved (equivalent Cα atoms within 0.2 Å). In hLonP, the catalytic Ser855 on α2 is hydrogen-bonded to Lys898 in α3 to form the Ser-Lys dyad. Thr880, the third residue, is hydrogen-bonded to Lys898 and possibly Ser855. There is a water molecule (Water3) bound to the Thr880 hydroxyl group. Lys898 is also H-bonded to Gly893.

The 310 helix at the N-terminal end of α2 brings an aspartate residue, Asp852, into the active site where its OD2 atom forms a hydrogen bond with Lys898 [Fig. 4(A)] and is only 3.2 Å from Ser855. In order for the lysine to work as a general base and abstract a proton from the nucleophilic serine, it must be in the deprotonated form. One contribution to lowering the pKa of the lysine is to place it in a hydrophobic environment. The interaction with Asp852 must affect the pKa of Lys898 and prevent its function as a general base. Perhaps more importantly, Asp852 and in addition Trp770 are placed so as to block access to the active site. Thus, it is most unlikely that the present conformation represents a catalytically active form of the hLonP domain.

Figure 4.

Figure 4

A: Active site of the hLon proteolytic domain with the 2FoFc electron density contoured at 1σ. The hydrogen bond network between the catalytic nucleophile Ser855, the general base Lys898 and Thr880 is shown. Asp852 can be seen to prevent access of substrate by H-bonding to Lys898. B: Superposition of the region around the active site of the hLonP domain (green) with those of the VP4 proteases from the infectious pancreatic necrosis virus (2pnl, coral) and the blotched snakehead virus (2gef, blue). The positions of the two residues of the catalytic dyad and the associated threonine are closely similar in the three structures.

The X-ray data and coordinates have been deposited in the PDB with the accession code 2x36.

Oligomerization and activity assays

To understand the relationship between oligomerization and activity of the hLon protease and to support the hypothesis of the relationship between oligomerization and activity (below), two constructs of hLon were prepared, corresponding to the full-length enzyme and the proteolytic domain (including residues 762–960). For each of them, the oligomeric state and peptidase activities were examined (Table I). The full-length construct formed a hexamer in solution and showed clear peptidase activity in the presence of ATP and also in the presence of nonhydrolyzable analogue AMP-PNP. In contrast, the protease domain on its own was monomeric in solution and possessed no peptidase activity.

Table I.

Oligomerization and Activity of Full-Length hLon and of the Proteolytic Domain Alone

Degree of oligomerization
Superose 12 gel filtration
Glutaraldehyde crosslinking
Peptidase relative activity (%)
Construct Hexamer Mixture Monomer Hexamer Mixture Monomer With ATP With AMP-PNP
hLon full length 98% 1% 1% >99% <1% 100 130
Proteolytic domain <1% >99% <1% >99% <0.1

Discussion

The structure of the human mitochondrial Lon protease proteolytic domain confirms it has an overall fold similar to the four known LonP structures in the PDB with an overall rmsd of 2.2 Å for the multiple superposition of 162 Cα atoms calculated using SSM.36 The major differences are in the loops connecting the various secondary structural elements. First, there is a significant difference at the N-terminus of α2, which affects the active site. Second, the loop between β2 and β3 is rather long and disordered in hLonP and AfLonP. It has been proposed25 that this loop might play a functional role in interacting with the ATPase domain. An interaction between these two domains was proposed earlier from yeast two-hybrid studies.20 Third, as in AfLonP, the N-terminal tail of hLonP points toward the active site surface rather than the putative AAA+ interface.

Superposition of the hLonP structure on those of the two Birnaviral VP4 proteases (PDB codes 2pnl and 2gef) shows that while the core of the domain is conserved, there are major deletions and insertions as could be expected from the very low level of sequence similarity. The VP4 structures will not be further discussed, but what is highly relevant to LonP is that the catalytic dyads of the two VP4 and three of the four LonP (the exception is AfLon) structures domains superimpose very closely [Fig. 4(B)]. Because for one of the VP4 structures the serine is trapped as a covalent intermediate, this provides compelling evidence that the two residues making up the dyad are in an appropriate orientation to function in proteolysis.

Comparison with other LonP structures

To assist in the following discussion, some salient points and key features in and around the active site of the four LonP structures are shown in Table II. In summary, we will argue that the closely similar hLonP and MjLonP structures represent a closed inactive monomeric (or dimeric) form of the domain, whereas EcLonP is an open active hexameric form. AfLonP presents something of an enigma, and the structure of AfLonP cannot be reconciled with our proposals for the other three structures, as in none the structures of its various mutants do the serine and lysine form the expected dyad, the serine pointing away in the opposite direction.

Table II.

Comparison of Key Properties and Nature of the Active Sites of the Four Known LonP Structures

hLonP MjLonP EcLonP AfLonP
PDB ID 1xhk 1rre 1z0w and so forth
LonA/B A B A B
Kingdom Eukaryote Archaea Eubacteria Archaea
Mutant S to A Some mutants
Oligomer Monomer/dimer Monomer (dimer not biological) Hexamer Monomers and hexamers
Active site 310 or β strand 310 310 β strand β strand in all
Extended loop contact to adjacent subunit in hexamer Cannot, as 310 Cannot, as 310 Yes Yes, but different from EcLonP
Ser-Lys Dyad Yes Yes Yes, mutant, modelled No
Asp blocking Active Site Yes Yes No No
Lysine Forms dyad, but buried by Asp Forms dyad, but buried by Asp Forms dyad Accessible but no dyad
Active site Closed form Closed form, inactive Open form, no Asp and Trp No dyad, serine points away
Proposed activity based on conformation Inactive Inactive Active with modeled serine Inactive, serine in wrong place to form dyad

As can be seen from Table II, the hLonP and MjLonP active sites are very similar to one another, and will be discussed first. Superposing the two structures brings the active site residues within 0.2 Å with highly conserved hydrogen-bonding interactions. In both structures, there is a 310 helix at the N-terminal end of α2 which brings an extra residue, Asp852, into the active site where it forms hydrogen bonds with Lys898 [Fig. 4(A)]. It was previously suggested for MjLon that this aspartate made up a pseudo-catalytic triad24; however, mutation of the equivalent glutamate (E506A) in AfLon does not abolish the ATP-dependent catalytic activity and has no effect on the ATP-independent activity, making it appear that the aspartate does not participate directly in catalysis.25 Furthermore, this helix blocks one end of the shallow groove seen in EcLonP that is postulated to participate in substrate binding. These considerations lead us to conclude that the conformation seen in hLonP and MjLonP represents an inactive state which may however represent an important mechanism for the proper regulation of the enzyme.

Although the sequence identity between the proteins in the area of the active site approaches 100%, the active site of the E. coli enzyme shows significant differences in 3D structure from those of hLonP and MjLonP. When compared with EcLonP, the loop connecting β1 and β2 in hLonP has shifted by 4.0 Å away from the active site and Trp770 has rotated so that the edge of the indole ring is now over the active site, putting this loop into a conformation similar to that seen in MjLon and AfLon and rather far from the equivalent residues in EcLonP. In EcLonP, the 310 helix at the N-terminal end of α2, which allows the aspartate to form hydrogen bonds with the catalytic Lys898, is transformed into β5 which causes the equivalent aspartate to move well away from the active site. This opens up the active site making the catalytic serine accessible to substrates and presumably removing the constraint on the pKa of the lysine. α1, in contrast, has moved about 2 Å away from the active site in hLonP, possibly as a result of loss of the interaction between the helix dipole and the equivalent Asp676 in EcLonP.

Thus, there are two quite distinct conformations in and around the active site, a closed form seen in hLonP and MjLonP where the active site is blocked by an aspartate, and an open form where the aspartate has moved away. In addition in the hLon monomer, Trp770 is positioned so as to block access to the active site. We propose that the former represents an inactive and the latter an active form. The stability of the two forms appears to be related to the oligomerization state of the domain.

Oligomerization and activity

The oligomerization state of Lon proteases in vivo remains somewhat uncertain. AfLonP and EcLonP are hexameric in the crystal,23,25 whereas transmission electron microscopy suggests that yeast Lon is heptameric.37 In hLonP, the two dimers in the crystal formed by chains A-B and chains C-D are closely similar to one another. In addition, they superpose well on two adjacent subunits of the E. coli hexamers, and it is possible to generate a model of a hLonP hexamer from three dimers. However, some key interactions in the interface are missing and conformational changes in the hLonP protomer would be required to convert the α-closed conformation seen here into the β-open conformation seen in the E. coli structure.

The balance between the interactions lost and gained between the two conformations appears to be delicate. We propose that both the conformations are likely to exist in the cell. It appears that the conformations seen in hLonP and MjLonP both correspond to that of an inactive monomeric form of the protein. In the EcLonP hexamer, there is a conformation in which the loop joining β4–α2 has formed a β-strand (β5 in E. coli) and also interacts with the neighboring subunit. In contrast, in the structures containing monomers, MjLonP and hLonP, there is a helix in the active site with an acidic residue forming hydrogen bonds or a salt bridge with the active site residues.

Our observations allow us to postulate a possible mechanism for the events following the oligomerization of hexameric Lon. In solution, it seems reasonable to suppose that the LonP monomers adopt the closed (α-helical conformation) seen in the present structure, based on the presence of this conformation in MjLon and in all protomers in hLon regardless of their association state. Following proper association into a hexameric ring, a conformational change is triggered, converting the hLonP-type conformation into the EcLonP form: the N-terminal 310 helical extension to α2 unwinds, bringing Asp852 into contact with the N-terminus of α1, causing it to move ∼2 Å closer to the active site and closing the cavity, we observed in the present structure [Fig. 3(C)]. The unwound helix, in turn, forms β5, whereas the loop connecting β5 with β4 is stabilized through interactions between Lys851 and the main-chain carbonyl atoms of Val844, Glu846, Thr849, and Gly804. This loop then interacts with the N-terminal region of α1 from the adjacent subunit. Because the unwinding of the α2 extension leads to both a shift of α1 in the same subunit and interactions between the newly formed loop and α1 of an adjacent subunit, it seems that this conformational change must be cooperative and may well require the formation of the hexamer. The formation of dimers in the hLonP crystals is insufficient to flip the molecule into the open form. Assuming the conformation of the active site seen in hLonP to be proteolytically inactive, this cooperative change would account for the observation that the presence of the hexamer is necessary for peptidase activity (below). Furthermore, this provides a mechanism by which the proteolytic domain might be regulated to prevent uncontrolled proteolysis, activity being dependent on the formation of hexamers through cooperative interactions involving both the AAA+ and the protoleolytic domains.

Although it has been determined that Glu506, the counterpart of Asp852 in AfLonP, is not necessary for proteolytic activity,25 it has been shown the equivalent residue is required for proteolytic activity in EcLon, where it interacts with the N-terminal part of α1, which contributes to the intersubunit contacts making up the hexamer. This led to the conclusion that the importance of this residue lay in its structural role in maintaining the correct overall fold.15 Although, in hLonP, in the absence of this particular interaction, α1 has moved away from the active site by about 2 Å and that the Lon hexamer has not formed, we do observe the presence of two dimers which appear to be components of a proposed hLonP hexamer.

The AfLonP hexamer shows neither the E. coli nor the human conformation. When comparing the AfLonP hexamer with hLonP and EcLonP, however, shows that it appears to be almost an intermediate form between the two. As in EcLonP, the loop between β4 and α2 has unwound and interacts with the neighboring subunit (albeit in a somewhat different manner). Similarly, it has formed part of β5. However, as in hLon, its N-terminal tail has been pushed into the cleft between the two domains, possibly disrupting the interface and preventing proper interaction. By preventing proper unfolding of this loop, this insertion may give rise to the unique conformation seen in the AfLonP active site. We cannot see how this conformation could be catalytically active given the absence of the serine-lysine dyad.

For this mechanism to be correct, the formation of the hexamer must be necessary for proteolytic activity to occur. This correlates nicely with the biochemical data where the full-length hLon is hexameric in solution and shows high peptidase activity both with ATP and with AMP-PNP (nonhydrolyzable analogue), in contrast to the protease domain alone which is a monomer in solution and shows no peptidase activity (Table I).

Although N-terminal degradation was observed in the crystallization solution, this is unlikely to be a result of proteolytic activity by Lon itself because the same pattern of degradation is seen when the S855A hLonP mutant is overexpressed and purified (data not shown). Furthermore, we tested hLonP samples of several concentrations for protease and peptidase activity under several possible crystallization conditions, and in all these cases, the cleavage pattern observed was the same. The addition of the inhibitors MG-132 and lactacystine, which completely block the peptidase activity of the full-length Lon, did not suppress this cleavage. Consequently, it is very unlikely that LonP, in any oligomeric state, could be responsible for the degradation that we see here.

An additional objection to this mechanism is raised by the mutant Lon expressed by the E. coli lonR9/capR9 gene.38 This mutant is able to form hexamers both with itself and mixed oligomers with EcLon wt,39 but it is proteolytically inactive. The only difference between EcLon and LonR9 seems to be an E614K point mutation. Glu614 is located in the subunit interface in the EcLonP structure as is Glu781, its equivalent in hLonP. In the EcLonP structure, Glu614 forms several H-bonds with both the main-chain atoms of Arg710 and Leu709 and with the side chain of Arg710 of the neighboring subunit. Furthermore, this residue is in Van der Waals contact with Pro669, which is part of the active site loop that unfolds to convert the inactive to the active conformation. Therefore, replacing Glu614 with Lys would be expected somewhat to disrupt the hexameric interface, but because this residue is toward the edge of the interface rather than the middle, it would probably not completely abolish it. However, because of its location immediately below the active site loop in the active conformation, it could also plausibly prevent the loop from properly unfolding from the inactive to the active form, in much the same way as the N-terminus of the AfLonP structure appears to prevent the correct active site conformation from forming. In other words, instead of preventing the hexamer from forming, this particular substitution should prevent LonR9 from forming the proteolytically active conformation seen in EcLonP; consequently, a crystal structure of the proteolytic domain of LonR9 or of the mutant E614K ought to show the inactive conformation seen here or, possibly, a conformation similar to that seen in AfLonP.

Materials and Methods

Purification

hLonP domain for crystallization (residues 741–959)

hLonP domain for crystallization (residues 741–959) was overproduced and purified from E. coli Rosetta2 cells (Novagen) transformed with the ProEx plasmid containing the hLonP domain with a 6 × Histag. Cells were grown in 3% bactotryptone, 2% yeast extract, 1% MOPS pH 7.5 at 37°C until the O.D. 600 nm reached 0.5. Overexpression of recombinant protein was induced by addition of IPTG to 1 mM and further growth of the cultures at 37°C for 90 min. Cells were lysed in 25 mM HEPES pH 8; 150 mM NaCl; 10% glycerol, 10 mM imidazole (Buffer A), and loaded onto a Ni2+-NTA affinity column. The column was washed with Buffer A containing 60 mM imidazole, and the tagged protein was eluted in Buffer A plus 250 mM imidazole. The peak containing the proteolytic domain was loaded onto an S200 gel filtration column equilibrated with 25 mM HEPES pH 8, 150 mM NaCl, and 10% glycerol. Fractions containing hLonP were dialyzed against 25 mM HEPES pH 8, 150 mM NaCl and concentrated to 15 mg/mL.

Purification of constructs for activity and oligomerization assay

Full-length human Lon and the hLonP were overproduced in and purified from the Rosetta E. coli strain (Novagen) transformed by plasmids bearing the hLon full length lacking its predicted mitochondrial targeting sequence and appropriate truncated form of hLon,40 all with a 6 × His tag at the N-terminus. The cells were harvested and suspended in buffer A (20 mM HEPES pH 8.0, 150 mM NaCl, 20% glycerol) and sonicated on ice. The lysate was centrifuged at 200,000g at 4°C for 10 min, and the supernatant was loaded onto a Ni2+-NTA column (Qiagen). The column was washed thrice with buffer A and five times with buffer A containing 40 mM imidazole. Full-length hLon and hLonP bound to the column were eluted in three steps with buffer A containing 0.1, 0.2, or 0.3M imidazole.

Multimer formation and stability determination by gel filtration and crosslinking

Gel filtration

Following purification, 6 × His-tagged Lon proteins were loaded in a volume of 200 μL onto a Superose 12 column (Pharmacia) equilibrated with 20 mM HEPES pH 8.0, 150 mM NaCl and 10% glycerol at 4°C. Standards used for size calibration were Blue dextran: 2000 kDa, apoferritin: 440 kDa, BSA: 66 kDa, albumin from hen egg white: 45 kDa, catalase: 232 kDa, aldolase: 158 kDa, carbonic anhydrase: 29 kDa, and cytochrome c from bovine heart: 13 kDa.

Chemical crosslinking

Crosslinking experiments were carried out as previously described.12,21 The two constructs (20 μg isolated on Ni2+-NTA) were crosslinked using 0.1% glutaraldehyde (Sigma) for 30 min on ice. Crosslinking was stopped by adding reducing sample buffer containing 1M urea and heating at 95°C. Visualization was done on a 3.3% SDS-PAGE stained with Coomassie Brilliant Blue.

Peptidase activity

Peptidase activity was assayed by the fluorescence method41 using Glu-Ala-Ala-Phe-MNA (GAAP-MNA) as a substrate in a reaction mixture containing 2 μg protease or hLonP domain, 50 mM Tris pH 7.9, 5 mM MgCl2, 0.3 mM fluorogenic peptide, 1 mM ATP or appropriate nonhydrolysable analogue at 37°C for 30 min. Fluorescence was measured on FilterFluorimetra (Model LS-2B, Perkin-Elmer, Anglicko) at excitation 340 nm and emission 410 nm.

Protein concentration

Protein concentration was estimate by BCA protein assay kit (Pierce Biotechnology) and verified by 10–12% SDS-PAGE and Coomassie staining.

Crystallization, structure solution, and refinement

Crystal screens PACT, HAMPTON I & II and INDEX were set up with protein at a concentration of 15 mg mL−1, using a Mosquito nanoliter-dispensing robot. Promising crystals were obtained following optimization of initial hits in condition F7 of the PACT screen, 0.1M Bis-Tris propanol pH 6.5, 0.25M sodium acetate, and 28% PEG 3350 with 5% glycerol. N-terminal sequencing from a dissolved crystal showed that the crystals contained residues 754–959 of hLonP implying that a 13 residue N-terminal truncation had occurred during crystallogenesis.

Data were collected at beamline ID14-4 at the European Synchrotron Radiation Facility (ESRF, Grenoble). Data were integrated using MOSFLM42 and scaled and reduced using the CCP4 suite of programs 6.1.0.43 Because of problems associated with twinning and anisotropic diffraction of the crystals, several data sets were collected, of which two were used in the final analysis: one extending to 2.4 Å resolution and the second to 2 Å (Table III). Identification of the correct space group proved to be something of a challenge. Both data sets were originally indexed and integrated in P21212, the orthorhombic space group indicated by POINTLESS.44 However, as described below, both were finally shown to be in space group P21. The value of the β angle was very close to 90° and indeed the value was just over 90° for the 2.4-Å data and just below for the 2-Å crystal. The data merged reasonably well in the orthorhombic space group, with the merging R factor being only a little higher when data were merged around the a* and c* axes than around b*.

Table III.

Data Collection and Refinement Statistics for the hLon Proteolytic Domain

2.4 Å Data 2 Å Data
Data collection
Space group P21 P21
Cell dimensions
a, b, c (Å) 68.24, 82.96, 105.29 69.80, 83.75, 105.49
α, β, γ (°) 90, 89.97, 90 90, 90.05, 90
Resolution (Å) 2.39 (2.52−2.39) 2 (2.11−2)
Rsym or Rmerge 0.096 (0.566) 0.063 (0.73)
I/σ (I) 14.4 (3.2) 10.9 (1.7)
Completeness (%) 98 (96.7) 99.4 (99.9)
Redundancy 5.5 (5.2) 3.6 (3.7)
Refinement
Resolution (Å) 2.39 2
No. reflections 42,707 77,079
Rwork/Rfree (%) 20.85/26.16 19.36/23.23
No. amino acid residues 1098 1100
No. atoms
Protein 8296 8373
Water 155 330
B-factors (Å2)
Protein 47.0 50.5
Water 44.9 51.6
R.m.s. deviations
Bond lengths (Å) 0.009 (0.022) 0.027 (0.022)
Bond angles (°) 1.147 (1.970) 2.095 (1.968)
Ramachandran plot (%)
Most favored 91.9 94.5
Additionally allowed 7.9 5.5
Generously allowed 0.2 0
Disallowed 0 0

The numbers in brackets refer to the outer resolution shell. A single crystal was used for each data set. The following residues are disordered an omitted from the final model: chain A: 756–953, loop from 788–797; chain B: 756–948, loop from 784–798; chain C: 755–953, loop from 788–796; chain D: 760–948, loop from 785–797; chain E: 758–948, loop from 786–797; chain F: 759–948, loop from 785–797. For the data collection, the numbers in parentheses correspond to the outer shell of reflections. For the refinement deviations, the values in parentheses are the target values.

The structure was first solved in P21212 using the 2.0 Å dataset by molecular replacement with MOLREP using the EcLon proteolytic domain (chain A of pdb entry 1rre) as the search model. This identified three independent protomers in the orthorhombic asymmetric unit. Manual corrections to the model were made using COOT45 and refinement was carried out with REFMAC.46 The resulting structure had an Rfree of 32% and satisfactory electron density for two of the three chains, but very poor density for the third.

This model was then placed in the cell for the 2.4 Å data and this structure refined, again in P21212. The refinement again halted at an Rfree around 30%. At this stage, the data were reinvestigated and reintegrated in the lower symmetry (and correct) P21 space group. In addition, the statistics clearly indicated that the data were twinned. Identification of the correct space group proved to be easier with the 2.4 Å crystals than for that at higher resolution. Refinement then continued with six independent molecules in the asymmetric unit using the recently implemented twinning mode and led to a much improved values for R and Rfree of 20.8% and 26.1%, respectively, and substantially improved density for the previously poorly ordered third protomer and its pseudo-symmetric mate. The twinning fraction was 0.68.

The 2.0 Å data were reprocessed in the correct P21 cell, and the model refined against these data to an R and Rfree of 19.36% and 23.23%, respectively, again with clear evidence for twinning. The details of data processing and quality of both models are presented in Table III. The data set (2.0 Å) had a twinning fraction of 0.77.

Summary

In summary, we propose that the monomeric form of LonP seen in the present structure and in MjLonP represent inactive conformations of the domain, preventing uncontrolled proteolysis. Formation of a catalytically active form requires the formation of the hexamer accompanied by a conformational change leading to a proteolytically active form similar to that seen in E. coli. This hypothesis is supported by our biochemical data.

Acknowledgments

The authors thank the staff at the ESRF (beamline ID14-4) for provision of synchrotron facilities, and Johan Turkenberg and Sam Hart for assistance with data collection.

References

  • 1.Gottesman S, Maurizi MR. Regulation by proteolysis: energy-dependent proteases and their targets. Microbiol Rev. 1992;56:592–621. doi: 10.1128/mr.56.4.592-621.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Schoemaker JM, Markovitz A. Identification of the gene Lon (capR) product as a 94-kilodalton polypeptide by cloning and deletion analysis. J Bacteriol. 1981;147:46–56. doi: 10.1128/jb.147.1.46-56.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ostersetzer O, Kato Y, Adam Z, Sakamoto W. Multiple intracellular locations of Lon protease in Arabidopsis: evidence for the localization of AtLon4 to chloroplasts. Plant Cell Physiol. 2007;48:881–885. doi: 10.1093/pcp/pcm052. [DOI] [PubMed] [Google Scholar]
  • 4.Wang N, Gottesman S, Willingham MC, Gottesman MM, Maurizi MR. A human mitochondrial ATP-dependent protease that is highly homologous to bacterial Lon protease. Proc Natl Acad Sci USA. 1993;90:11247–11251. doi: 10.1073/pnas.90.23.11247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kikuchi M, Hatano N, Yokota S, Shimozawa N, Imanaka T, Taniguchi H. Proteomic analysis of rat liver peroxisome: presence of peroxisome-specific isozyme of Lon protease. J Biol Chem. 2004;279:421–428. doi: 10.1074/jbc.M305623200. [DOI] [PubMed] [Google Scholar]
  • 6.Petropoulos I, Friguet B. Maintenance of proteins and aging: the role of oxidized protein repair. Free Radical Res. 2006;40:1269–1276. doi: 10.1080/10715760600917144. [DOI] [PubMed] [Google Scholar]
  • 7.Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria and neurodegeneration. Biosci Rep. 2007;27:87–104. doi: 10.1007/s10540-007-9038-z. [DOI] [PubMed] [Google Scholar]
  • 8.Bota DA, Davies KJ. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat Cell Biol. 2002;4:674–680. doi: 10.1038/ncb836. [DOI] [PubMed] [Google Scholar]
  • 9.Fu GK, Markovitz DM. The human LON protease binds to mitochondrial promoters in a single-stranded, site-specific, strand-specific manner. Biochemistry. 1998;37:1905–1909. doi: 10.1021/bi970928c. [DOI] [PubMed] [Google Scholar]
  • 10.Chen SH, Suzuki CK, Wu SH. Thermodynamic characterization of specific interactions between the human Lon protease and G-quartet DNA. Nucleic Acids Res. 2008;36:1273–1287. doi: 10.1093/nar/gkm1140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lu B, Yadav S, Shah PG, Liu T, Tian B, Pukszta S, Villaluna N, Kutejova E, Newlon CS, Santos JH, Suzuki CK. Roles for the human ATP-dependent Lon protease in mitochondrial DNA maintenance. J Biol Chem. 2007;282:17363–17374. doi: 10.1074/jbc.M611540200. [DOI] [PubMed] [Google Scholar]
  • 12.Liu T, Lu B, Lee I, Ondrovicova G, Kutejova E, Suzuki CK. DNA and RNA binding by the mitochondrial Lon protease is regulated by nucleotide and protein substrate. J Biol Chem. 2004;279:13902–13910. doi: 10.1074/jbc.M309642200. [DOI] [PubMed] [Google Scholar]
  • 13.Cheng X, Kanki T, Fukuoh A, Ohgaki K, Takeya R, Aoki Y, Hamasaki N, Kang D. PDIP38 associates with proteins constituting the mitochondrial DNA nucleoid. J Biochem (Tokyo) 2005;138:673–678. doi: 10.1093/jb/mvi169. [DOI] [PubMed] [Google Scholar]
  • 14.Bogenhagen DL, Rousseau D, Burke S. The layered stucture of human mitochondrial DNA nucleoids. J Biol Chem. 2008;283:3665–3675. doi: 10.1074/jbc.M708444200. [DOI] [PubMed] [Google Scholar]
  • 15.Rotanova TV, Melnikov EE, Khalatova AG, Makhovskaya OV, Botos I, Wlodawer A, Gustchina A. Classification of ATP-dependent proteases Lon and comparison of the active sites of their proteolytic domains. Eur J Biochem. 2004;271:4865–4871. doi: 10.1111/j.1432-1033.2004.04452.x. [DOI] [PubMed] [Google Scholar]
  • 16.Lee AY, Hsu CH, Wu SH. Functional domains of Brevibacillus thermoruber Lon protease for oligomerization and DNA binding: role of N-terminal and sensor and substrate discrimination domains. J Biol Chem. 2004;279:34903–34912. doi: 10.1074/jbc.M403562200. [DOI] [PubMed] [Google Scholar]
  • 17.Li M, Rasulova F, Melnikov EE, Rotanova TV, Gustchina A, Maurizi MR, Wlodawer A. Crystal structure of the N-terminal domain of E. coli Lon protease. Protein Sci. 2005;14:2895–2900. doi: 10.1110/ps.051736805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ogura T, Wilkinson AJ. AAA+ superfamily ATPases: common structure—diverse function. Genes Cells. 2001;6:575–597. doi: 10.1046/j.1365-2443.2001.00447.x. [DOI] [PubMed] [Google Scholar]
  • 19.Botos I, Melnikov EE, Cherry S, Khalatova AG, Rasulova FS, Tropea JE, Maurizi MR, Rotanova TV, Gustchina A, Wlodawer A. Crystal structure of the AAA+ alpha domain of E. coli Lon protease at 1.9A resolution. J Struct Biol. 2004;146:113–122. doi: 10.1016/j.jsb.2003.09.003. [DOI] [PubMed] [Google Scholar]
  • 20.Rasulova FS, Dergousova NI, Mel'nikov EE, Ginodman LM, Rotanova TV. [Synthesis and characterisation of ATP-dependent forms of Lon-proteinase with modified N-terminal domain from Escherichia coli] Bioorg Khim. 1998;24:370–375. [PubMed] [Google Scholar]
  • 21.van Dijl JM, Kutejova E, Suda K, Perecko D, Schatz G, Suzuki CK. The ATPase and protease domains of yeast mitochondrial Lon: roles in proteolysis and respiration-dependent growth. Proc Natl Acad Sci USA. 1998;95:10584–10589. doi: 10.1073/pnas.95.18.10584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rasulova FS, Dergousova NI, Starkova NN, Melnikov EE, Rumsh LD, Ginodman LM, Rotanova TV. The isolated proteolytic domain of Escherichia coli ATP-dependent protease Lon exhibits the peptidase activity. FEBS Lett. 1998;432:179–181. doi: 10.1016/s0014-5793(98)00859-x. [DOI] [PubMed] [Google Scholar]
  • 23.Botos I, Melnikov EE, Cherry S, Tropea JE, Khalatova AG, Rasulova F, Dauter Z, Maurizi MR, Rotanova TV, Wlodawer A, Gustchina A. The catalytic domain of Escherichia coli Lon protease has a unique fold and a Ser-Lys dyad in the active site. J Biol Chem. 2004;279:8140–8148. doi: 10.1074/jbc.M312243200. [DOI] [PubMed] [Google Scholar]
  • 24.Im YJ, Na Y, Kang GB, Rho SH, Kim MK, Lee JH, Chung CH, Eom SH. The active site of a Lon protease from Methanococcus jannaschii distinctly differs from the canonical catalytic Dyad of Lon proteases. J Biol Chem. 2004;279:53451–53457. doi: 10.1074/jbc.M410437200. [DOI] [PubMed] [Google Scholar]
  • 25.Botos I, Melnikov EE, Cherry S, Kozlov S, Makhovskaya OV, Tropea JE, Gustchina A, Rotanova TV, Wlodawer A. Atomic-resolution crystal structure of the proteolytic domain of Archaeoglobus fulgidus Lon reveals the conformational variability in the active sites of Lon proteases. J Mol Biol. 2005;351:144–157. doi: 10.1016/j.jmb.2005.06.008. [DOI] [PubMed] [Google Scholar]
  • 26.Luo Y, Pfuetzner RA, Mosimann S, Paetzel M, Frey EA, Cherney M, Kim B, Little JW, Strynadka NC. Crystal structure of LexA: a conformational switch for regulation of self-cleavage. Cell. 2001;106:585–594. doi: 10.1016/s0092-8674(01)00479-2. [DOI] [PubMed] [Google Scholar]
  • 27.Paetzel M, Dalbey RE, Strynadka NC. Crystal structure of a bacterial signal peptidase apoenzyme: implications for signal peptide binding and the Ser-Lys dyad mechanism. J Biol Chem. 2002;277:9512–9519. doi: 10.1074/jbc.M110983200. [DOI] [PubMed] [Google Scholar]
  • 28.Feldman AR, Lee J, Delmas B, Paetzel M. Crystal structure of a novel viral protease with a serine/lysine catalytic dyad mechanism. J Mol Biol. 2006;358:1378–1389. doi: 10.1016/j.jmb.2006.02.045. [DOI] [PubMed] [Google Scholar]
  • 29.Lee J, Feldman AR, Delmas B, Paetzel M. Crystal structure of the VP4 protease from infectious pancreatic necrosis virus reveals the acyl-enzyme complex for an intermolecular self-cleavage reaction. J Biol Chem. 2007;282:24928–24937. doi: 10.1074/jbc.M701551200. [DOI] [PubMed] [Google Scholar]
  • 30.Birghan C, Mundt E, Gorbalenya AE. A non-canonical Lon proteinase lacking the ATPase domain employs the ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus. EMBO J. 2000;19:114–123. doi: 10.1093/emboj/19.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P, Murshudov GN, Cohen S, Perrakis A, Noble M. Developments in the CCP4 molecular-graphics project. Acta Crystallogr Sect D. 2004;60:2288–2294. doi: 10.1107/S0907444904023716. [DOI] [PubMed] [Google Scholar]
  • 32.Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–4680. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gouet P, Courcelle E, Stuart DI, Metoz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics. 1999;15:305–308. doi: 10.1093/bioinformatics/15.4.305. [DOI] [PubMed] [Google Scholar]
  • 34.Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774–797. doi: 10.1016/j.jmb.2007.05.022. [DOI] [PubMed] [Google Scholar]
  • 35.Liao DI, Qian J, Chisholm DA, Jordan DB, Diner BA. Crystal structures of the photosystem II D1 C-terminal processing protease. Nat Struct Biol. 2000;7:749–753. doi: 10.1038/78973. [DOI] [PubMed] [Google Scholar]
  • 36.Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr Sect D. 2004;60:2256–2268. doi: 10.1107/S0907444904026460. [DOI] [PubMed] [Google Scholar]
  • 37.Stahlberg H, Kutejova E, Suda K, Wolpensinger B, Lustig A, Schatz G, Engel A, Suzuki CK. Mitochondrial Lon of Saccharomyces cerevisiae is a ring-shaped protease with seven flexible subunits. Proc Natl Acad Sci USA. 1999;96:6787–6790. doi: 10.1073/pnas.96.12.6787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chung CH, Waxman L, Goldberg AL. Studies of the protein encoded by the Lon mutation, capR9, in Escherichia coli. A labile form of the ATP-dependent protease La that inhibits the wild type protease. J Biol Chem. 1983;258:215–221. [PubMed] [Google Scholar]
  • 39.Oh JY, Eun YM, Yoo SJ, Seol JH, Seong IS, Lee CS, Chung CH. LonR9 carrying a single Glu614 to Lys mutation inhibits the ATP-dependent protease La (Lon) by forming mixed oligomeric complexes. Biochem Biophys Res Commun. 1998;250:32–35. doi: 10.1006/bbrc.1998.9252. [DOI] [PubMed] [Google Scholar]
  • 40.Ondrovicová G, Liu T, Singh K, Tian B, Li H, Gakh O, Perecko D, Janata J, Granot Z, Orly J, Kutejová E, Suzuki CK. Cleavage site selection within a folded substrate by the ATP-dependent Lon protease. J Biol Chem. 2005;280:25103–25110. doi: 10.1074/jbc.M502796200. [DOI] [PubMed] [Google Scholar]
  • 41.Goldberg AL, Moerschell RP, Chung CH, Maurizi MR. ATP-dependent protease La (Lon) from Escherichia coli. Methods Enzymol. 1994;244:350–375. doi: 10.1016/0076-6879(94)44027-1. [DOI] [PubMed] [Google Scholar]
  • 42.Leslie AG. Integration of macromolecular diffraction data. Acta Crystallogr Sect D. 1999;55:1696–1702. doi: 10.1107/s090744499900846x. [DOI] [PubMed] [Google Scholar]
  • 43.Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr Sect D. 1994;50:760–763. doi: 10.1107/S0907444994003112. [DOI] [PubMed] [Google Scholar]
  • 44.Evans P. Scaling and assessment of data quality. Acta Crystallogr Sect D. 2006;62:72–82. doi: 10.1107/S0907444905036693. [DOI] [PubMed] [Google Scholar]
  • 45.Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  • 46.Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr Sect D. 1997;53:240–255. doi: 10.1107/S0907444996012255. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES